診斷用酵素的全球市場:現狀分析、預測(2022年～2028年)

全球診斷用酵素的市場規模，由於診斷技術的創新高漲，及酵素為基礎的診斷檢驗的採用持續增加，預計以約4％穩定成長。還有各種感染疾病和慢性疾病的盛行率上升，是診斷用酵素市場的主要成長促進因素之一。

本報告提供全球診斷用酵素市場相關調查分析，各市場區隔、各地區的市場洞察，市場動態，市場趨勢，競爭情形，企業簡介等系統性資訊。

目錄

第1章 市場簡介

第2章 調查手法、前提條件

第3章 市場概要

第4章 摘要整理

第5章 COVID-19對診斷用酵素市場的影響

第6章 診斷用酵素市場收益(2020年～2028年)

第7章 市場洞察:各類型

• Taq聚合酵素
• RNase抑制劑
• Cas9酵素
• 酸性磷酸酶
• 葡萄糖氧化酵素/葡萄糖去氫酵素
• 尿素酶
• 乳酸氧化酶
• 其他

第8章 市場洞察:各用途

• 感染疾病
• 自體免疫疾病
• 腫瘤學
• 心臟病
• 腎臟學
• 糖尿病
• 其他

第9章 市場洞察:各產品類型

• 分子酵素
• 臨床酵素

第10章 市場洞察:各終端用戶

• 醫院
• 臨床檢驗室
• 其他

第11章 市場洞察:各地區

• 北美
  • 美國
  • 加拿大
  • 其他北美
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 其他地區

第12章 診斷用酵素:市場動態

• 推動市場要素
• 市場課題
• 影響分析

第13章 診斷用酵素:市場機會

第14章 診斷用酵素:市場趨勢

第15章 需求側、供給側的分析

• 需求面分析
• 供給側分析

第16章 價值鏈分析

第17章 競爭模式

• 競爭情形
  • 波特的五力分析

第18章 企業概要

• Takara Bio, Inc.
• Promega Corporation
• Enzo Life Sciences, Inc.
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Creative Enzymes
• F. Hoffmann-La Roche Ltd.
• Solis BioDyne
• Ampliqon A/S
• Genzyme Corporation

第19章 免責聲明

Enzymes are proteins with highly specialized catalytic functions, produced by all living organisms. The metabolic activity of all living creatures, including plants, microbes, animals, and mankind, depends on enzymes. Because of their excellent bio-catalytic properties, enzymes are frequently used in the detection of numerous disorders. Several metabolic problems can be caused by enzyme abnormalities. As a result, elements of the enzyme metabolism systems have been used as unique markers for the diagnosis of diseases. The prompt control of the transmission of infectious diseases and the reduction of the dangers to public health depends on the adoption of proper diagnostic enzyme techniques. Therefore, the rising prevalence of various infectious & chronic diseases is one of the major factors responsible for the growth of the diagnostic enzymes market. For instance, as per the World Health Organization 2020, the global impact of infectious disease by the SARS-CoV-2 outbreak (COVID-19), caused over 13.3 million infections and 782,000 deaths globally.

The Diagnostic Enzymes Market is expected to grow at a steady rate of around 4% owing to the increasing adoption of enzyme-based diagnostic tests coupled with the growing innovations in diagnostics technologies. Major players in the market offer innovative developments in the biotechnology domain with technologically advanced features. For instance, in January 2021, Creative Enzymes launched a complete product portfolio of diagnostic enzymes for medical and research diagnosis.

Based on type, the diagnostic enzymes market is segmented into Taq polymerase, RNase inhibitors, cas9 enzyme, acid phosphatase, glucose oxidase/glucose dehydrogenase, urease, lactate oxidase, and others. The glucose oxidase/glucose dehydrogenase segment accounted for a significant market share in 2020 owing to its several advantages such as its abundance, biocompatibility, and lack of toxicity. Furthermore, the entry of global players into emerging markets adds to the growth of the market during the forecast period.

On the basis of application, the diagnostic enzymes market is segmented into infectious diseases, autoimmune diseases, oncology, cardiology, nephrology, diabetes, and others. Among these, the infectious diseases segment to hold a significant share of the market in 2020. This is mainly due to the rising incidence of infectious diseases, that require early detection using these enzymes. For instance, according to the CDC/National Center for Health Statistics, 2022, the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis in the US was 3.4 million. Therefore, infectious diseases such as typical pneumonia, TB, streptococcal pharyngitis, ulcerative urogenital infections, and a number of chronic conditions can be easily diagnosed with enzyme-based techniques like PCR.

Based on product type, the diagnostic enzymes market has been classified into molecular enzymes and clinical enzymes. The molecular enzymes category holds a major share of the market during the forecast period. This is mainly due to the rising research and adoption of molecular enzymes in molecular diagnostics. Different enzymes are mostly used through methods like PCR tests, NGS assays, and others. One of the most used molecular biology methods is PCR. The technology is being used more and more in a variety of industries, such as cloning, sequencing, forensic investigation, and diagnostic testing.

For a better understanding of the market adoption of the Diagnostic Enzymes industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the increased need for enzymes and the rising incidence of infectious diseases in the region which has become dominant. In order to combat the continuing epidemic, the FDA has approved COVID-19 laboratory-developed diagnostics for emergency use. The majority of these emergency usage authorizations also make use of RT-PCR-based testing and enzyme-linked immunosorbent assays for the identification of SARS-CoV-2. The creation of such tests is anticipated to be profitable in the North American market because of the high usage of enzymes during RT-PCR.

Some of the major players operating in the market include: Takara Bio, Inc., Promega Corporation, Enzo Life Sciences, Inc., Merck KGaA, Thermo Fisher Scientific, Inc., Creative Enzymes, F. Hoffmann-La Roche Ltd., Solis BioDyne, Ampliqon A/S, and Genzyme Corporation

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Diagnostic Enzymes Market
• 2.2. Research Methodology of the Diagnostic Enzymes Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE DIAGNOSTIC ENZYMES MARKET

6 DIAGNOSTIC ENZYMES MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TYPE

• 7.1. Taq Polymerase
• 7.2. RNase Inhibitors
• 7.3. Cas9 Enzyme
• 7.4. Acid Phosphatase
• 7.5. Glucose Oxidase/Glucose Dehydrogenase
• 7.6. Urease
• 7.7. Lactate Oxidase
• 7.8. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Infectious Diseases
• 8.2. Autoimmune Diseases
• 8.3. Oncology
• 8.4. Cardiology
• 8.5. Nephrology
• 8.6. Diabetes
• 8.7. Others

9 MARKET INSIGHTS BY PRODUCT TYPE

• 9.1. Molecular Enzymes
• 9.2. Clinical Enzymes

10 MARKET INSIGHTS BY END USERS

• 10.1. Hospitals
• 10.2. Clinical Laboratories
• 10.3. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 DIAGNOSTIC ENZYMES MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 DIAGNOSTIC ENZYMES MARKET OPPORTUNITIES

14 DIAGNOSTIC ENZYMES MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Takara Bio, Inc.
• 18.2. Promega Corporation
• 18.3. Enzo Life Sciences, Inc.
• 18.4. Merck KGaA
• 18.5. Thermo Fisher Scientific, Inc.
• 18.6. Creative Enzymes
• 18.7. F. Hoffmann-La Roche Ltd.
• 18.8. Solis BioDyne
• 18.9. Ampliqon A/S
• 18.10. Genzyme Corporation

19 DISCLAIMER